Alkem Laboratories informs about press release

15 Mar 2021 Evaluate

Alkem Laboratories has informed that Company has launched Brivaracetam in India under the brand name ‘Brivasure’, an affordable anti-epileptic drug for the treatment of Epilepsy in India. Brivasure has received authorization from the Drug Controller General of India (DCGI). In this regard, the company has enclosed a press release on 15th March 2021 titled ‘Alkem makes epilepsy treatment more accessible & affordable with the launch of Brivasure (Brivaracetam)’.

The above information is a part of company’s filings submitted to BSE.

Alkem Laboratories Share Price

4857.90 146.00 (3.10%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.